Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase III, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
An Open-label, Multicenter Phase Ib Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of the ATR Inhibitor M1774 in combination with DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors.
Study Type: Treatment
Phase: I
NCTID: NCT05396833
Principal Investigator:
Melissa Javellana
Understanding the Impact of Drug Shortages on Oncology Care Delivery
The Effectiveness of Lactobacillus Plantarum LBP in Preventing Acute Graft-Versus-Host Disease GvHD in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation HCT
Study Type: Prevention
Phase: III
NCTID: NCT03057054
Principal Investigator:
Keith August
Phase 3 Study PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib versus Physician?s Choice in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia Platelet Counts < 50,000/�L
NCI COVID-19 in Cancer Patients Study NCCAPS: A Longitudinal Natural History Study
A Phase 2 Study of DS-8201a NSC 807708 in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma
Study Type: Treatment
Phase: II
NCTID: NCT04616560
Principal Investigator:
Kevin Ginn
Open Label Phase II Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors
Randomized Phase II/III Study of Venetoclax ABT 199 Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Study Type: Treatment
Phase: II/III
NCTID: NCT03984448
Principal Investigator:
Marc Hoffmann